CG Oncology, Inc. - 8-K Filing
CG Oncology held its 2026 Annual Meeting of Stockholders on June 4, 2026. Shareholders elected two Class II directors (Christina Rossi and Victor Tong, Jr.), ratified Ernst & Young LLP as the independent auditor for fiscal year ending December 31, 2026, approved executive compensation advisory vote, and voted to hold annual advisory votes on executive pay. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $CGON